Major CDMO expands sterile fill-finish capacity in Ireland

A major CDMO's new sterile fill-finish suite in Ireland adds meaningful biologics capacity to a market segment that has been capacity-constrained since 2023.

A major European contract development and manufacturing organisation (CDMO) has announced GMP readiness for its new sterile fill-finish suite in Ireland, following a successful EMA inspection in June 2026. The facility adds vial and pre-filled syringe capacity for biologics, addressing a bottleneck that has constrained injectable supply chains since the post-pandemic capacity crunch of 2023.

Sponsors currently operating with single-source fill-finish agreements or managing injectables through constrained EU capacity should reassess their qualified supplier shortlists. The new suite is EMA-certified and positioned for both clinical and commercial manufacturing. Full facility profile, capacity details, and qualification status are tracked in Nexigen.